European Society for Medical Oncology (ESMO)

Small-cell lung cancer (SCLC) extensive stage (ES) in Spain: review of demographic, epidemiological and clinical data from the Thoracic Tumors Registry (TTR study).

Small-cell lung cancer (SCLC) extensive stage (ES) in Spain: efficacy of treatments, data from the Thoracic Tumors Registry (TTR study).

Durvalumab after chemoradiotherapy in Stage III NSCLC: 4-year survival update from the Phase 3 PACIFIC trial

Description of the clinical characteristics and survival in patients with NSCLC in the Spanish population: an analysis of the Thoracic Tumors Registry.

A phase 3, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)

PD-L1 expression and survival in stage III unresectable non-small cell lung cancer patients in Denmark

Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Durvalumab compared to maintenance chemotherapy in patients with metastatic non-small cell lung cancer: Results from the randomized SAFIR02 LUNG-IMMUNO trial

MEDINDUCTION: Phase I trial evaluating the safety of durvalumab in combination with Docetaxel, Cisplatin and 5-FU (DCF) as induction therapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN)

Phase Ib/II study of durvalumab and guadecitabine in advanced clear cell Renal Cell Cancer (ccRCC).

Extended follow-up of DURVAST trial: a phase 2 study evaluating Durvalumab treatment in HIV-1-infected Patients with Solid Tumors by the Spanish Lung Cancer Group

Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: a phase 1/2 trial

Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): preliminary results from a multicenter study (IFCT-1601 IONESCO).

Cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy: safety and preliminary activity of the open-label, single-arm, phase 2 ARCADIA trial

Precision Immuno-Oncology for advanced Non-Small Cell Lung Cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): a first analysis of the PIONeeR Study

SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial

CALIBRATION: Can early changes in circulating tumour DNA (ctDNA) predict durable tumor responses in patients (pts) with advanced Esophageal Adenocarcinoma (EAC) receiving anti PD-L1 antibody durvalumab (D)?

Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D) in advanced solid tumors (AST): dose finding results

Durvalumab (D) in combination with chemoradiotherapy (CRT) in solid tumours: Phase 1 CLOVER study

NEMIO: a randomized phase I-II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma

A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)

Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D): efficacy and safety preliminary results of the advanced breast cancer (ABC) patients (pts) cohort of the MOVIE study

Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

A phase 3 trial of capivasertib and fulvestrant versus placebo and fulvestrant in patients with HR+/HER2− breast cancer (CAPItello-291)

A Phase 1, First-in-Human, Multicenter, Open-Label, Dose-Escalation Study of IPH5201 as Monotherapy or in Combination With Durvalumab ± Oleclumab in Advanced Solid Tumors

Safety and efficacy of MEDI0457 plus durvalumab in patients with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC)

MEDI1191, a novel IL-12 mRNA therapy for intratumoral injection to promote TH1 transformation of the tumor microenvironment

First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 Oleclumab (O) to the anti-PD-L1 Durvalumab (D) and Chemotherapy (ChT) as 1st line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)

Assessing clinical benefit of olaparib maintenance treatment in subgroups of patients with germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPC): Phase III POLO trial

Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1

Tolerability of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Phase III PROfound trial

Final overall survival (OS) analysis of PROfound: olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

First real-life data on Olaparib in 1st line (1stL) maintenance BRCA1/2 mutated Epithelial Ovarian Cancer (EOC) in France: Descriptive analysis of 201 patients (pts) enrolled in the Cohort Temporary Authorization for Use (ATUc)

Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the Phase III PAOLA-1 trial

Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high‐grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the Phase III PAOLA-1/ENGOT-ov25 trial

Exploring the impact of treatment switching on the interim overall survival results of the PROfound study in HRR-mutated mCRPC

Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332)

Real-World Treatment (Tx) Patterns of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients (pts) in the US

Real-World Patterns of Genomic Testing in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Real-World Treatment (Tx) Patterns in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Homologous Recombination Repair Mutations (HRRm+)

Genomic/genetic testing (GT) patterns for patients with metastatic castrate-resistant prostate cancer (mCRPC): interim results from a real-world study in Europe (EU5)

Extended follow-up of a real-life cohort of olaparib maintenance in patients with BRCAm relapsed epithelial ovarian cancer (EOC).The GINECO RETROLA study

Olaparib maintenance therapy in German routine clinical practice – Quality of life interim results of the non-interventional C-PATROL study

Prevalence of BRCA1/2 Mutations in Patients with Ovarian Cancer in the Gulf Region: The PREDICT Study

Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo:the SOLO2/ENGOT Ov-21 trial

Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: results from the randomized phase II CLIO trial

GEICO1601-ROLANDO: A multicentric single arm Phase II clinical trial to evaluate the combination of olaparib (OLA) and pegylated liposomal doxorubicin (PLD) for platinum-resistant ovarian cancer (PROC)

DNA Damage Repair (DDR) gene mutations (mut) are predictors of response to platinum-based chemotherapy in advanced pancreatic cancer (PC) patients (pts)

Phase Ib expansion study of adavosertib plus olaparib in patients with extensive-stage or relapsed small-cell lung cancer

Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)

Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer. NEODURVARIB Trial

A randomized phase II study of osimertinib with or without bevacizumab in advanced lung adenocarcinoma patients with EGFR T790M mutation (West Japan Oncology Group 8715L)

FACILITATE: a real-world multicentre prospective study investigating the utility of a rapid, fully automated RT-PCR assay vs reference methods (RM) for detecting epidermal growth factor receptor mutations (EGFRm) in NSCLC

Real-world EGFR testing in patients with EGFRm advanced NSCLC in Belgium (REVEAL)

Real-world treatment patterns of patients with locally advanced/metastatic EGFRm NSCLC in Belgium (REVEAL)

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFR mutated (EGFRm) advanced NSCLC: FLAURA China study overall survival (OS)

Epidermal growth factor receptor mutation (EGFRm) testing in advanced non-small cell lung cancer (aNSCLC) in a real-world setting

Osimertinib plus platinum/pemetrexed in newly-diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: safety run-in results from the FLAURA2 study

Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): central nervous system (CNS) disease recurrence

Real-world treatment patterns, clinical outcomes and EGFR/T790M testing practices in patients with EGFRm advanced NSCLC and 1L EGFR TKI therapy - a retrospective multinational study (REFLECT)

A phase 1b/2, multicenter, open-label, dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd; DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03)

Artificial intelligence analysis of advanced breast cancer patients from a phase I trial of Trastuzumab Deruxtecan (T-DxD): HER2 and histopathology features as predictors of clinical benefit

Patient Preferences for HER2-Targeted Treatment of Advanced or Metastatic Breast Cancer in the United States

Risk Factors for Interstitial Lung Disease in Patients Treated With Trastuzumab Deruxtecan From Two Interventional Studies

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2 low advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: exploratory cohorts of the phase 2, multicenter, open-label DESTINY-Gastric01 study

 

The Drug Rediscovery Protocol (DRUP): results of the first 500 treated patients

Abdominal events of targeted therapies – report from the Drug Rediscovery Protocol (DRUP)